ERBB2 and neoplasm: Together, these data indicate that DFTD tumor cells, which express high levels of phosphorylated ERBB2 and ERBB3 and show activation of the ERBB signaling pathway, are exquisitely vulnerable to ERBB kinase inhibitors.